Can a single intraoperative dose of non-steroidal anti-inflammatory drugs reduce cancer recurrence?
Editorial

Can a single intraoperative dose of non-steroidal anti-inflammatory drugs reduce cancer recurrence?

Maria F. Ramirez1,2, Laura Garcia2,3, Juan P. Cata1,2

1Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Anesthesiology and Surgical Oncology Research Group, Houston, TX, USA; 3Department of Anesthesiology, National Cancer Institute, Mexico City, Mexico

Correspondence to: Juan P. Cata, MD. Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX 77005, USA. Email: JCata@mdanderson.org.

Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Palliative Medicine. The article did not undergo external peer review.

Comment on: Mao S, Wu Y, Wang R, et al. Intraoperative use of single dose of nonsteroidal anti-inflammatory drugs was not associated with cancer recurrence and mortality after bladder cancer surgery: a retrospective study. Ann Palliat Med 2020;9:8-18.


Submitted Jan 31, 2020. Accepted for publication Feb 11, 2020.

doi: 10.21037/apm.2020.02.24


We read with great interest the article by Mao et al. entitled “Intraoperative use of single dose of nonsteroidal anti-inflammatory drugs was not associated with cancer recurrence and mortality after bladder cancer surgery: a retrospective study”. Their study addressed an interesting topic in perioperative oncology medicine that is the association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and cancer-related outcomes after bladder cancer surgery. The authors performed a single center, retrospective study to investigate the association between a single intraoperative dose of parecoxib and mortality, recurrence-free survival and overall survival. They included 185 patients and concluded that the intraoperative administration of 40 mg of parecoxib was not associated with a decreased in overall mortality or a benefit in recurrence-free or overall survivals.

According to the American Institute for Cancer Research, bladder cancer is the most common malignancy of the urinary system (1). In 2018, approximately 500,000 new cases of bladder cancer were diagnosed worldwide, thus making it the 10th most common malignancy overall (2). The mortality rate is still high with only 70% of patients with localized disease alive 5-year after initial treatment. In those with metastatic disease to lymph nodes or distant organs the 5-year survival rates are 35% and 5%, respectively. These worrisome statistics along with the financial burden on the society has encouraged scientists to better understand the biology of bladder cancer.

A number of laboratory studies have examined the relationship between NSAIDs use and cancer risk. NSAIDs are thought to protect against carcinogenesis and tumor progression by inhibiting cyclooxygenase (COX) (3). COX converts arachidonic acid to prostaglandins (PGs) and the PGs overexpression is key during the early steps in a variety of oncogenic events (4). Furthermore, NSAIDs can block tumor cell proliferation, migration and invasion, inhibit tumor angiogenesis (throughout the reduction of VEGF expression), and promote programmed cell death (5-7). Thus, it has been speculated that NSAIDs could reduce the pro-tumoral effects associated with surgery including inflammation and angiogenesis (8).

When examining the literature, one can erroneously conclude that the results from Mao et al. are opposing to the findings reported in a meta-analysis conducted by Zhang et al. and a pooled analysis by Daugherty et al. Zhang’s meta-analysis included seventeen studies (8 cohort and 9 cases-control studies) involving a total of 1,008,800 participants, including 10,618 bladder cancer cases. The study involved 3 categories of analgesic: acetaminophen, aspirin and non-aspirin NSAIDs. Six studies were used for analysis of non-aspirin NSAIDs with a total of 761,687 participants. The study period was variable (2–20 years). They reported that non-aspirin NSAIDs use was significantly associated with reduced risk of bladder cancer among case-control studies but not cohort studies. In addition, the study found that non-aspirin NSAIDs use was associated with a 43% reduction in bladder cancer among smokers but not among current smokers. Unfortunately, there was significant heterogeneity among studies (9). Daugherty et al. also investigated the association of NSAIDs and bladder cancer in 3 large prospective studies (NIH-AARP Diet and Health Study; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; and U.S. Radiologic Technologist Study). The analysis included 508,842 patients with 2,489 incident cases of bladder cancer. They observed a reduction of bladder cancer risk for patients who reported regular use (>2 times/weeks) of non-aspirin NSAIDs compared with those who reported no use. The association was found for non-smokers only. No significant heterogeneity was observed (10). The most obvious difference between these studies and Mao’s work is that the formers were focused on the so-called “chemo-preventive” effects of NSAIDs, which are typically observed after their prolonged. In other terms, the beneficial effects of NSAIDs in bladder cancer might be seen after prolonged exposure and not after a single administration, as it occurred in Mao’s work (parecoxib 40 mg).

However, as we mentioned previously, a group of investigators have suggested that the single administration of NSAIDs can offer protective effects against growth of the postoperative minimal residual disease (8). Forget et al. conducted a retrospective analysis of 720 cancer patients undergoing conservative breast cancer surgery. In that study a single dose of either ketorolac 30 mg or diclofenac 75 mg was associated with an improved disease-free survival and an improved overall survival (11). Similar results were also found and reported by the same group of researchers after prostate and lung cancers surgery (12). Differences in tumor sensitivity to different NSAIDs could explain the discrepancies in outcomes between studies. For instance, urogenital tumor cells are particularly sensitive to ibuprophen-induced expression of P75NTR tumor suppressor gene (5). Other NSAIDs including indomethacin, sulindac, ketoprophen and piroxicam that have shown anti-tumor effects; however, there are not in vitro or in vivo studies that demonstrate an anti-tumoral effect of the parecoxib on tumor cells. Thus, one could speculate that the protective effect might vary according to NSAID class (13-15). Last, the current studies on the effect of NSAIDs on cancer recurrence after surgery are mostly retrospective. These studies have limitations in particular, significant bias and confounding. Unable to control for possible confounders such as concomitant drugs administrations, quality of surgical resection and blood transfusions are always a source of misinterpretation of the data.

In our opinion, it remains unclear whether NSAIDs are associated with reduced recurrence or longer overall survival after cancer surgery. It is unlikely that a single dose of any NSAID will prolong survival after oncological procedures. However, a prolonged perioperative treatment (before and after surgery) with NSAIDs may overcome the impact of surgery on cancer spread. Only well designed randomized controlled trials will help to determine the clinical benefits of these drugs.


Acknowledgments

Funding: None.


Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/apm.2020.02.24). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 2015;29:177-89. vii. [Crossref] [PubMed]
  2. Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018;74:784-95. [Crossref] [PubMed]
  3. Hashemi Goradel N, Najafi M, Salehi E, et al. Cyclooxygenase-2 in cancer: a review. J Cell Physiol 2019;234:5683-99. [Crossref] [PubMed]
  4. Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int 2015;15:106. [Crossref] [PubMed]
  5. Khwaja F, Allen J, Lynch J, et al. Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. Cancer Res 2004;64:6207-13. [Crossref] [PubMed]
  6. Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58. [Crossref] [PubMed]
  7. Čeponytė U, Paškevičiūtė M, Petrikaitė V. Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures. Cancer Manag Res 2018;10:1543-51. [Crossref] [PubMed]
  8. Forget P, De Kock M. A single intraoperative dose of original ketorolac to prevent cancer recurrence: Is that too simple? Louvain Medical 2014;133:391-5.
  9. Zhang H, Jiang D, Li X. Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studies. PLoS One 2013;8:e70008. [Crossref] [PubMed]
  10. Daugherty SE, Pfeiffer RM, Sigurdson AJ, et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 2011;173:721-30. [Crossref] [PubMed]
  11. Forget P, Bentin C, Machiels JP, et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth 2014;113 Suppl 1:i82-7. [Crossref] [PubMed]
  12. Forget P, Machiels JP, Coulie PG, et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 2013;20 Suppl 3:S650-60. [Crossref] [PubMed]
  13. Grubbs CJ, Juliana MM, Eto I, et al. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res 1993;13:33-6. [PubMed]
  14. Moon RC, Kelloff GJ, Detrisac CJ, et al. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 1994;14:5-11. [PubMed]
  15. Rao KV, Detrisac CJ, Steele VE, et al. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:1435-8. [Crossref] [PubMed]
Cite this article as: Ramirez MF, Garcia L, Cata JP. Can a single intraoperative dose of non-steroidal anti-inflammatory drugs reduce cancer recurrence? Ann Palliat Med 2020;9(3):625-627. doi: 10.21037/apm.2020.02.24